lomonitinib - Artificial Intelligence News Briefing

Expert Systems Celebrates Completion Of Single Dose Studies And Start Of Multiple Human Dosing For Lomonitinib, A Selective Pan-flt3/irak4 Inhibitor, Achieved In Just 3 Years

Expert Systems Fuzzy Logic February 23, 2024

Expert Systems and Eilean Therapeutics have successfully completed a Phase 1 clinical trial for lomonitinib, a potential treatment for FLT3-mutated AML. The drug has…

Subscribe to Updates

Browsing: lomonitinib

Expert Systems Celebrates Completion Of Single Dose Studies And Start Of Multiple Human Dosing For Lomonitinib, A Selective Pan-flt3/irak4 Inhibitor, Achieved In Just 3 Years